Should I buy or sell Entera Bio stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ENTX shares. View ENTX analyst ratings or view top-rated stocks .

What is Entera Bio's stock price target for 2024?

1 brokers have issued 12-month target prices for Entera Bio's shares. Their ENTX share price targets range from $10.00 to $10.00. On average, they anticipate the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 402.5% from the stock's current price. View analysts price targets for ENTX or view top-rated stocks among Wall Street analysts .

How have ENTX shares performed in 2024?

Entera Bio's stock was trading at $0.60 on January 1st, 2024. Since then, ENTX stock has increased by 231.7% and is now trading at $1.99. View the best growth stocks for 2024 here .

Are investors shorting Entera Bio?

Entera Bio saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 88,200 shares, an increase of 988.9% from the March 15th total of 8,100 shares. Based on an average daily volume of 161,500 shares, the days-to-cover ratio is currently 0.5 days. View Entera Bio's Short Interest .

When is Entera Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our ENTX earnings forecast .

How were Entera Bio's earnings last quarter?

Entera Bio Ltd. (NASDAQ:ENTX) posted its earnings results on Friday, March, 8th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01.

What other stocks do shareholders of Entera Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Fulcrum Therapeutics (FULC) , Cara Therapeutics (CARA) , Gilead Sciences (GILD) , Supernus Pharmaceuticals (SUPN) , VIVUS (VVUS) , Vaxart (VXRT) , AbbVie (ABBV) , Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA) .

When did Entera Bio IPO?

Entera Bio (ENTX) raised $11 million in an initial public offering on Thursday, June 28th 2018. The company issued 1,400,000 shares at $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager.

How do I buy shares of Entera Bio?

Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ENTX

Entera Bio (ENTX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ENTX Stock Alerts

$1.99

-0.25 (-11.16%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.95
▼
$2.29
50-Day Range: $0.85
▼
$2.98
52-Week Range: $0.52
▼
$3.35

Volume: 300,731 shs
Average Volume: 412,561 shs
Market Capitalization: $57.31 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Get Entera Bio alerts:

Entera Bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 402.5% Upside
$10.00 Price Target
Short Interest: Healthy
0.31% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.25) to ($0.54) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.75 out of 5 stars

Medical Sector

619th out of 911 stocks

Biological Products, Except Diagnostic Industry

106th out of 152 stocks

3.5

Analyst's Opinion

Consensus Rating
Entera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Entera Bio has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.31% of the outstanding shares of Entera Bio have been sold short.
Short Interest Ratio / Days to Cover
Entera Bio has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Entera Bio has recently increased by 988.89%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Entera Bio does not currently pay a dividend.
Dividend Growth
Entera Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ENTX.

3.9

News and Social Media Coverage

News Sentiment
Entera Bio has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Entera Bio this week, compared to 0 articles on an average week.
Search Interest
19 people have searched for ENTX on MarketBeat in the last 30 days. This is an increase of 375% compared to the previous 30 days.
MarketBeat Follows
7 people have added Entera Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Entera Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.90% of the stock of Entera Bio is held by insiders.
Percentage Held by Institutions
Only 14.11% of the stock of Entera Bio is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Entera Bio are expected to decrease in the coming year, from ($0.25) to ($0.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Entera Bio is -6.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Entera Bio is -6.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Entera Bio has a P/B Ratio of 5.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Entera Bio Stock (NASDAQ:ENTX)

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

ENTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ENTX Stock News Headlines

April 15, 2024 | investorplace.com

Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?

April 8, 2024 | globenewswire.com

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 26, 2024 | globenewswire.com

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

March 23, 2024 | finance.yahoo.com

We Think Entera Bio (NASDAQ:ENTX) Can Afford To Drive Business Growth

March 20, 2024 | globenewswire.com

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

March 12, 2024 | finanznachrichten.de

Entera Bio Ltd.: Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

March 9, 2024 | finance.yahoo.com

ENTX May 2024 5.000 call

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 8, 2024 | globenewswire.com

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

March 6, 2024 | investing.com

Entera Bio regains NASDAQ compliance with bid price

March 4, 2024 | finanznachrichten.de

Entera Bio Ltd.: Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

March 4, 2024 | globenewswire.com

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

February 17, 2024 | finance.yahoo.com

ENTX Mar 2024 2.500 call

January 30, 2024 | finance.yahoo.com

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

January 20, 2024 | ca.finance.yahoo.com

ENTX Jan 2024 10.000 call

January 3, 2024 | finance.yahoo.com

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

December 31, 2023 | benzinga.com

Entera Bio Stock (NASDAQ:ENTX), Short Interest Report

December 27, 2023 | benzinga.com

Entera Bio Stock (NASDAQ:ENTX) Dividends: History, Yield and Dates

December 26, 2023 | benzinga.com

Entera Bio Stock (NASDAQ:ENTX), Analyst Ratings, Price Targets, Predictions

December 26, 2023 | finance.yahoo.com

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

November 29, 2023 | finance.yahoo.com

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform

November 27, 2023 | msn.com

Entera Bio (ENTX) Price Target Increased by 66.67% to 10.20

November 14, 2023 | baystreet.ca

Entera Bio Flat on Release of Q3 Numbers

November 14, 2023 | msn.com

Entera Bio GAAP EPS of -$0.08

November 14, 2023 | finance.yahoo.com

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

November 11, 2023 | morningstar.com

Entera Bio Ltd ENTX

See More Headlines

Receive ENTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/08/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/03/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ENTX
CUSIP: N/A
CIK: 1638097
Web: www.enterabio.com
Phone: (722) 532-7151
Fax: N/A
Employees: 17
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $10.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +402.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.31)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,890,000.00
Net Margins: N/A
Pretax Margin: -71,042.87%
Return on Equity: -101.78%
Return on Assets: -83.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.32
Quick Ratio: 10.32

Sales & Book Value

Annual Sales: $130,000.00
Price / Sales: 440.86
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.36 per share
Price / Book: 5.53

Miscellaneous

Outstanding Shares: 28,800,000
Free Float: 26,240,000
Market Cap: $57.31 million
Optionable: Optionable
Beta: 1.70

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Ms. Miranda J. Toledano M.B.A. (Age 47)
CEO & Director
Comp: $418k
Ms. Dana Yaacov-Garbeli CPA (Age 41)
Chief Financial Officer
Comp: $193k
Dr. Hillel Galitzer M.B.A. (Age 46)
Ph.D., Chief Operating Officer
Comp: $296k
Dr. Arthur C. Santora II (Age 73)
M.D., Ph.D., Chief Medical Officer
Comp: $355k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ENTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Entera Bio stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ENTX shares.
View ENTX analyst ratings or view top-rated stocks.
What is Entera Bio's stock price target for 2024?: 1 brokers have issued 12-month target prices for Entera Bio's shares. Their ENTX share price targets range from $10.00 to $10.00. On average, they anticipate the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 402.5% from the stock's current price.
View analysts price targets for ENTX or view top-rated stocks among Wall Street analysts.
How have ENTX shares performed in 2024?: Entera Bio's stock was trading at $0.60 on January 1st, 2024. Since then, ENTX stock has increased by 231.7% and is now trading at $1.99.
View the best growth stocks for 2024 here.
Are investors shorting Entera Bio?: Entera Bio saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 88,200 shares, an increase of 988.9% from the March 15th total of 8,100 shares. Based on an average daily volume of 161,500 shares, the days-to-cover ratio is currently 0.5 days.
View Entera Bio's Short Interest.
When is Entera Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our ENTX earnings forecast.

How were Entera Bio's earnings last quarter?: Entera Bio Ltd. (NASDAQ:ENTX) posted its earnings results on Friday, March, 8th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01.
What other stocks do shareholders of Entera Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA).
When did Entera Bio IPO?: Entera Bio (ENTX) raised $11 million in an initial public offering on Thursday, June 28th 2018. The company issued 1,400,000 shares at $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager.
How do I buy shares of Entera Bio?: Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ENTX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial